Farris Maryanne MaunsellVP, Chief Accounting Officer
4
Filed Nov 13, 2026Period of report Nov 11, 20260000313143-26-000155
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
SaleNov 11, 2026 | Common StockF3F1 | 836 | $120.99 | $101.15K | 5,828 | Direct |
Filing footnotes · 4
- F1This number includes unvested restricted stock units ("RSUs") previously reported.
- F2Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- F4Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.